XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENTED INFORMATION
3 Months Ended
Mar. 31, 2023
SEGMENTED INFORMATION  
SEGMENTED INFORMATION

NOTE 11 - SEGMENTED INFORMATION

 

At March 31, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

 

 

 

BioNexus Gene Lab Corp.

(a Wyoming company)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 100%

 

 

 

 100%

 

 

 

Bionexus Gene Lab Sdn Bhd

(a Malaysia company)

 

 

 

 

Chemrex Corporation Sdn Bhd

(a Malaysia Company)

 

 

For the quarter ended March 31, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$7,436

 

 

$2,369,769

 

 

$-

 

 

$2,377,205

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(5,347)

 

 

(2,002,961)

 

 

-

 

 

 

(2,008,308 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS /PROFIT

 

 

2,089

 

 

 

366,808

 

 

 

-

 

 

 

368,897

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

1,126

 

 

 

116,218

 

 

 

-

 

 

 

117,344

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(46,255)

 

 

(383,177)

 

 

(107,440)

 

 

(536,872)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT FROM OPERATIONS

 

 

(43,040)

 

 

99,849

 

 

 

(107,440)

 

 

(50,631)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(666)

 

 

(1,779)

 

 

-

 

 

 

(2,445)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(43,706)

 

 

98,070

 

 

 

(107,440)

 

 

(53,076)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(15,990)

 

 

-

 

 

 

(15,990)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(43,706)

 

$82,080

 

 

$(107,440)

 

$(69,066)

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2022

 

REVENUE

 

$24,269

 

 

$3,004,676

 

 

$-

 

 

$3,028,945

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(8,038)

 

 

(2,664,574)

 

 

-

 

 

 

(2,672,612)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

16,231

 

 

 

340,102

 

 

 

-

 

 

 

356,333

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

2,076

 

 

 

44,306

 

 

 

12

 

 

 

46,394

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(44,042)

 

 

(297,769)

 

 

(26,225)

 

 

(368,036)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT FROM OPERATIONS

 

 

(25,735)

 

 

86,639

 

 

 

(26,213)

 

 

34,691

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(799)

 

 

(2,527)

 

 

-

 

 

 

(3,326)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX

 

 

(52,269)

 

 

170,751

 

 

 

(52,426)

 

 

31,365

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(14,299)

 

 

-

 

 

 

(14,299)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET PROFIT/(LOSS)

 

$(52,269)

 

$502,730

 

 

$(52,426)

 

$17,066

 

 

 

 

As of March 31, 2023 and December 31, 2022

 

 

 

Total Assets

 

 

 Total Liabilities

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BGLC & Bionexus

 

$509,574

 

 

$677,477

 

 

$93,034

 

 

$108,390

 

Chemrex

 

 

7,677,067

 

 

 

8,062,685

 

 

 

1,536,699

 

 

 

1,966,759

 

TOTAL

 

 

8,186,641

 

 

 

8,740,162

 

 

 

1,629,733

 

 

 

2,075,149